Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ: ALLO )

1.870 +0.030 (+1.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
Expert Ratings for Allogene Therapeutics
Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings: 
Via Benzinga
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
-Clinical Data Due Next Week at ASH- 
Via Benzinga
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET 
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Apple, Amazon, HP And Other Big Losers From Friday
U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion. 
Via Benzinga
What 5 Analyst Ratings Have To Say About Allogene Therapeutics
  Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
  
Via Benzinga
Allogene Therapeutics: Q2 Earnings Insights
  Allogene Therapeutics (NASDAQ:ALLO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET 
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022
  
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
Via Benzinga
What 4 Analyst Ratings Have To Say About Allogene Therapeutics
Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
U.S. FDA Grants Orphan-Drug Designation for Allogene's ALLO-605 for multiple myeloma
Allogene Therapeutics, Inc. (Nasdaq: ALLO) received Orphan-drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its drug candidate ALLO-605 for the treatment of patients with... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.